Ludvig from Norway

Registered at the short selling broker IQ Option, 2 minutes ago.

» Try IQ Option you too
87% of retail investor accounts lose money when trading CFDs with IQ Option.
Don't show again

Novartis AG (NVS) shares information

Novartis AG – ADR


24h Change

0.48 %

NVS

Live rate: Market closed

Stock data per Friday 25 Nov, 2022

NVS
NEW YORK STOCK EXCHANGE INC.
87.29
86.92
87.71
0.42 (+ 0.48%)
US Market is closed

Live Stock price in graph for Novartis AG – ADR (NVS)

  • Latest Volume

    971,323 (-17.96 %)

  • Volume prev. day

    1,183,981

  • Avg. daily volume

    2,180,818

  • Market cap

    210,830,391,013

  • P/E ratio

    8.94

  • Today high

    87.795 USD

  • Today low

    86.85 USD

  • 52 week high

    94.26 USD

  • 52 week low

    74.09 USD

  • YTD Change

    + 4.95 %

Quick links

 

Latest news about Novartis AG – ADR

Below you can find the most recent news posts about Novartis AG – ADR, primarily from US and UK based news sources.

Novartis to advance malaria program into PhIII in bid to fight drug resistance

Wednesday, 23 November 2022, 16:56:44
Novartis is moving an anti-malaria drug into a Phase III trial that it hopes could provide a new weapon against drug-resistant strains of the infection. The company and its Swiss non-profit partner Medicines for Malaria Venture, or MMV, announced Wednesday that they are moving forward with the treatment, which uses
— Endpoints News


Novartis” Malaria Treatment Candidate To Move Forward With Phase 3 Development Next Year

Wednesday, 23 November 2022, 16:36:55
Novartis AG (NYSE: NVS ) and Medicines for Malaria Venture (MMV) have decided to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase 3 development for the treatment of patients with acute uncomplicated malaria. Ganaplacide is a novel agent with a new mechanism of action combined with a new formulation of lumefantrine optimized for once-daily dosing. This combination has the potential not only to … Full story available on Benzinga.com
— Benzinga


Novartis, MMV to advance new malaria therapy in phase 3 trial

Wednesday, 23 November 2022, 11:25:21
Novartis (NVS) and Medicines for Malaria Venture ((MMV)) have decided to advance ganaplacide/lumefantrine- solid dispersion formulation ((SDF)) into phase 3 development to treat…
— Seeking Alpha


Immunocell Therapy Market Competitive Analysis with Growth Forecast 2022 to 2028 | Gilead Sciences, Novartis

Wednesday, 23 November 2022, 06:33:42
The Global Immunocell Therapy Market can be obtained through the market details such as growth drivers, latest developments, Immunocell Therapy market business strategies, regional study, and future market status. The report also covers information including Immunocell Therapy industry latest opportunities
— OpenPR


Novartis claims two firms are infringing its patent for multiple sclerosis drug

Monday, 21 November 2022, 18:53:40
The medicine is used in the treatment of relapsing-remitting multiple sclerosis and contains the active ingredient fingolimod
— The Irish Times


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have NVS available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.